Literature DB >> 22939275

Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2.

N Witting1, M Duno, J Vissing.   

Abstract

Becker muscular dystrophy features progressive proximal weakness, wasting and often focal hypertrophy. We present a patient with pain and cramps from adolescence. Widespread muscle hypertrophy, preserved muscle strength and a 10-20-fold raised CPK were noted. Muscle biopsy was dystrophic, and Western blot showed a 95% reduction of dystrophin levels. Genetic analyses revealed a non-sense mutation in exon 2 of the dystrophin gene. This mutation is predicted to result in a Duchenne phenotype, but resulted in a mild Becker muscular dystrophy with widespread muscle hypertrophy. We suggest that this unusual phenotype is caused by translation re-initiation downstream from the mutation site.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22939275     DOI: 10.1016/j.nmd.2012.07.004

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  6 in total

Review 1.  Becker muscular dystrophy: case report, review of the literature, and analysis of differentially expressed hub genes.

Authors:  Min Li; Yongli Han; Shuying Wang; Yajie Yu; Mengling Liu; Yingfeng Xia; Ze'an Weng; Ling Zhou; Xiaoyan He; Jun Wang; Zhi He; Liang Yu; Yunhong Zha
Journal:  Neurol Sci       Date:  2021-11-03       Impact factor: 3.307

2.  Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression.

Authors:  Nanna Witting; Morten Duno; Helle Petri; Thomas Krag; Henning Bundgaard; Lars Kober; John Vissing
Journal:  J Neurol       Date:  2013-05-14       Impact factor: 4.849

3.  Activating internal ribosome entry to treat Duchenne muscular dystrophy.

Authors:  Shireen R Lamandé; Kathryn N North
Journal:  Nat Med       Date:  2014-09       Impact factor: 53.440

4.  Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice.

Authors:  Nicolas Wein; Adeline Vulin; Maria S Falzarano; Christina Al-Khalili Szigyarto; Baijayanta Maiti; Andrew Findlay; Kristin N Heller; Mathias Uhlén; Baskar Bakthavachalu; Sonia Messina; Giuseppe Vita; Chiara Passarelli; Simona Brioschi; Matteo Bovolenta; Marcella Neri; Francesca Gualandi; Steve D Wilton; Louise R Rodino-Klapac; Lin Yang; Diane M Dunn; Daniel R Schoenberg; Robert B Weiss; Michael T Howard; Alessandra Ferlini; Kevin M Flanigan
Journal:  Nat Med       Date:  2014-08-10       Impact factor: 53.440

5.  Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.

Authors:  Zhi Yon Charles Toh; May Thandar Aung-Htut; Gavin Pinniger; Abbie M Adams; Sudarsan Krishnaswarmy; Brenda L Wong; Sue Fletcher; Steve D Wilton
Journal:  PLoS One       Date:  2016-01-08       Impact factor: 3.240

6.  Targeted exon skipping to correct exon duplications in the dystrophin gene.

Authors:  Kane L Greer; Hanns Lochmüller; Kevin Flanigan; Susan Fletcher; Steve D Wilton
Journal:  Mol Ther Nucleic Acids       Date:  2014-03-18       Impact factor: 10.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.